anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study focuses on the experiences of older parents who have an adult child with intellectual disabilities (ID), specifically exploring their overall experiences and relationships with their offspring. A qualitative methodology incorporating semi-structured interviews was employed. Participants comprised sixteen older parents to an adult child with mild to moderate ID living in a residential village. Participants described various challenges, including physical and health-related difficulties and loneliness. Interviewees also expressed positive life experiences, such as engaging in new activities and pursuits. Parents noted a newfound balance in their parent-child relationships, affording them more time for personal interests in older adulthood, which they found to be unique opportunities distinct from their earlier years. It is recommended that interactions between older and younger parents of children with ID be fostered, facilitating opportunities for the younger generation to benefit from the experiences of their more seasoned counterparts.
The invention provides a process for the preparation of a bioadhesive laminate comprising a hot-melt extruded reservoir layer and a hot-melt extruded backing layer is provided. The reservoir layer comprises a thermoplastic bioadhesive composition containing an active agent. An active agent-containing thermoplastic bioadhesive hydrophilic composition is hot-melt coextruded with a hydrophobic composition to form at least a bi-layered laminate. The hydrophilic composition and the hydrophobic composition have at least one polymer in common. In addition, the melt flow index of the hydrophobic composition is within 50% of the melt flow index of the hydrophilic composition. As a result, the laminate has a uniform transverse cross-section and/or a uniform longitudinal cross-section throughout a major of the length of the laminate. Moreover, when the laminate is divided into unit doses of approximately the same size, they have a high degree of content uniformity with respect to the active agent(s) present therein.
The Look AHEAD trial has demonstrated improved risk factor control among overweight or obese diabetes patients who received an intensive lifestyle intervention at both one and four years after enrollment. Translating such findings into accessible and effective weight loss programs is a major public health challenge. We are conducting "Lifestyle Interventions for Treatment of Diabetes" (LIFT Diabetes). The overall goal is to investigate two approaches to improving risk factor control; one which is modeled after Look AHEAD and is designed to achieve 7% weight loss and increase physical activity to \> 175 minutes per week among minority and lower income diabetes patients via a 12-month, group based lifestyle intervention, using community health workers supervised by an interventionist. Participants will have up to 4 group visits/month and up to 12 individual contacts/year. The other approach will promote Diabetes Self Management (DSM) by educating participants regarding health behaviors which lead to improved diabetes control; this arm is also 12 months, and is delivered in the clinic by intervention staff via monthly group visits and up to 12 individual contacts/year. We will randomize 260 overweight or obese adults with diabetes to either intervention, and determine the impact on outcomes (UKPDS-estimated CVD risk, risk factor control), weight, cost, resource utilization, and safety at 12 months, and after transitioning back to usual care, at 24 months. The hypotheses are that the community based intervention results in 10% relative reduction in CVD risk compared to clinic-based intervention; the interventions are equivalent with respect to adherence and participant satisfaction; and the community based intervention is associated with lower cost than the clinic based intervention. Translating evidence based, lifestyle strategies, and targeting minority and underserved patients, will yield, if successful, models for addressing diabetes-related health disparities.
A randomized, crossover, double-blind, placebo-controlled, one-session clinical trial with 30 male volunteers was performed by applying a microneedle patch in the following regions of the oral cavity: lip (inner lower), buccal (cheek: 1 cm behind the month angle), tongue (dorsal surface), hard palate (anterior region), and attached gingiva (between central and lateral upper incisors). A 30 gauge hypodermic needle and an identical patch but without microneedles sticking out, were used as positive and negative controls, respectively. The application force was standardized to 10N by an applicator composed of a 5 mL syringe and a spring. Insertions were performed with a gap of 30 seconds. Pain and discomfort associated to the procedure was evaluated with a Visual Analogue Scale (VAS), by a blinded-dentist. The safety associated to microneedle application was verified immediately after the application (0h) and after the next day (24h). The different application sites were inspected visually for bleeding, ulceration, bruising, redness or swelling.
The invention relates to a chicken-derived antibacterial peptide. The sequence of the antibacterial peptide is as follows: <xnotran> MHCLKIMAFLLFFSLLLSQVYCASLHQPQP LLRLKRMTPFWRGVSLRPVGASCRKNSKCITMLCRKNRCFLRTASE, SEQ ID NO:1. </xnotran> The improved chicken antibacterial peptide LEAP-2 contains 76 amino acid residues, has the molecular weight of 8847.8Da, the isoelectric point of 10.61, the positive charge of 13, the instability coefficient of 48.95 and the total average hydrophobicity of 0.195. The preparation method of the improved chicken-derived antibacterial peptide LEAP-2 comprises the following steps: constructing a prokaryotic expression vector pET28a, transforming BL21, inducing expression and purifying protein. The chicken-derived antibacterial peptide can be more efficiently expressed, has broad-spectrum antibacterial property, and compared with the original chicken-derived antibacterial peptide LEAP-2, the improved chicken-derived antibacterial peptide LEAP-2 has high antibacterial activity which is remarkably abnormal and stable and is not easy to inactivate. The chicken-derived antibacterial peptide has the instability coefficient of 48.95, and compared with the original chicken-derived antibacterial peptide, the stability is improved by 11.4 percent.
Compositions comprising 1,3-propanediol and an extraction product are provided, and the 1,3-propanediol in the composition is biologically derived. Also provided are processes for extracting an extract from a source. These processes comprise providing an ester of 1,3-propanediol and mixing the 1,3-propanediol ester with the source. This serves to extract the extract from the source into the ester. The processes also include separating the source from the ester and extract. Also provided are compositions comprising an ester of 1,3-propanediol and an extraction product. In these compositions, the ester can have at least 3% biobased carbon.
Quetiapine therapy was initiated at 12.5 mg twice daily a. After thefirst dose of quetiapine 12.5 mg, the regimen could then be adjusted by the rounding surgeon. If the surgeon felt benefit from receiving a higher dose of quetiapine the dose could then be increased. Quetiapine was discontinued if adverse events (torsades de pointes or other ventricular tachycardias) occurred. All patients receiving at least one dose of quetiapine were included in the final intention-to-treat analyses. All prescribing decisions were left to the discretion of the rounding surgeon and were not mandated as part of the study.
Young adults between 18 and 35 years old will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
PURPOSE:To prepare a lipid component having high solubility in oily component and excellent oxidation stability and antiseptic preservability, by homogenizing the cerebral tissue of a mammal with an organic solvent miscible with water, filtering the mixture, and extracting the residue with an organic solvent, etc. having low polarity. CONSTITUTION:The cerebral tissue of a mammal is homogenized in the presence of an organic solvent miscible with water (e.g. methanol), and the component soluble in said organic solvent is extracted and removed. The residue is extracted with an organic solvent having low polarity (e.g. n-hexane) or its mixture with a lower alcohol (e.g. methanol), and the obtained extract is washed with water or a salt solution to obtain the objective lipid componet. USE:Emulsifier for food, cosmetic, drug for external application, etc.
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are now recommended for patients with heart failure, but the mechanisms that underlie the protective role of SGLT2i in cardiac remodeling remain unclear. Aldehyde dehydrogenase 2 (ALDH2) effectively prevents cardiac remodeling. Here, the key role of ALDH2 in the efficacy of SGLT2i on cardiac remodeling was studied.
METHODS: Analysis of multiple transcriptomic datasets and two-sample Mendelian randomization were performed to find out the differentially expressed genes between pathological cardiac hypertrophy models (patients) and controls. A pathological cardiac hypertrophy mouse model was established via transverse aortic constriction (TAC) or isoproterenol (ISO). Cardiomyocyte-specific ALDH2 knockout mice (ALDH2CMKO) and littermate control mice (ALDH2flox/flox) were generated to determine the critical role of ALDH2 in the preventive effects of dapagliflozin (DAPA) on cardiac remodeling. RNA sequencing, gene knockdown or overexpression, bisulfite sequencing PCR, and luciferase reporter assays were performed to explore the underlying molecular mechanisms involved.
RESULTS: Only ALDH2 was differentially expressed when the differentially expressed genes obtained via Mendelian analysis and the differentially expressed genes obtained from the multiple transcriptome datasets were combined. Mendelian analysis revealed that ALDH2 was negatively related to the severity of myocardial hypertrophy in patients. DAPA alleviated cardiac remodeling in mouse hearts subjected to TAC or ISO. ALDH2 expression was reduced, whereas ALDH2 expression was restored by DAPA in hypertrophic hearts. Cardiomyocyte specific ALDH2 knockout abolished the protective role of DAPA in preventing cardiac remodeling. ALDH2 expression and activity were increased in DAPA-treated neonatal rat primary cardiomyocytes (NRCMs), H9C2 cells and AC16 cells. Moreover, DAPA upregulated ALDH2 in peripheral blood mononuclear cells (PBMCs) from patients with type 2 diabetes. Sodium/proton exchanger 1 (NHE1) inhibition contributed to the regulation of ALDH2 by DAPA. DAPA suppressed the production of reactive oxygen species (ROS), downregulated DNA methyltransferase 1 (DNMT1) and subsequently reduced the ALDH2 promoter methylation level. Further studies revealed that DAPA enhanced the binding of nuclear transcription factor Y, subunit A (NFYA) to the promoter region of ALDH2, which was due to the decreased promoter methylation level of ALDH2.
CONCLUSIONS: The upregulation of ALDH2 plays a critical role in the protection of DAPA against cardiac remodeling. DAPA enhances the binding of NFYA to the ALDH2 promoter by reducing the ALDH2 promoter methylation level through NHE1/ROS/DNMT1 pathway.
Pharmaceutical compsns. contg. 1-Ar-3-NRR1-4-R5-r-R4-2-pyra zolines of formula (I) or their salts are new: (where Ar is an opt. substd. nitro or bicyclic aromatic or N-contg. heteroaromatic gp. with 5-10 ring atoms R is (i) H, (ii) alkyl opt. substd. by opt. substd. phenyl or 3-6C cycloalkyl, or (iii) alkenyl or alkynyl R1 is as defined for R but not H R4 and R5 are H or alkyl). Cpds. (I) are new, provided that NRR1 is not NMe2, NHEt or NEt2 when Ar is unsubstd. phenyl. Intermediates of formula Ar-N(NH2)-CR4-CR5-CONRR1 (II) are also new. - (I) are antiinflammatory and antiallergic agents which act by inhibiting arachidonic acid metabolism via lipoxygenase and cyclooxygenase and by inhibiting leukotriene and prostaglandin synthesis. They can be used for treatment or prophylaxis of inflammations, pain, pyrexia and asthma, for reducing tissue necrosis associated with chronic inflammatory disorders, and for suppressing tissue rejection after surgical transplantation. Effective doses are 0.5-50mg/kg.
ABSTRACT OF THE DISCLOSURE:           The present invention is concerned with a composi-tion for treatment and metaphylaxis of urate and mixed urate lithiase comprising, as active component, a non-ionogenic surfactant having a general formula RCOO(CH2CH2O)nH in which R represents a radical or linolic acid or linolenic acid or oleinic acid and n is a number from 18 to 40.  This therapeutic composition is acting on the principle of forming complex water-soluble components with the uric acid present in the urate concrements, dissolving the latter and elimi-nating the uric acid through the urine.  The action is achieved very fast without the occurence of secondary effects.  The composition can be applied also in the case of infected forms of urate lithiase as well as in the mixed forms of the same.  The pH of the urine is unchanged thus preventing the precipitation of phosphate.  A very fast convalescense of the sick persons is attained.
The invention involves the discovery that Chlamydia sp. strains can be cured of their plasmids by treatment with novobiocin, and that plasmid-deficient strains are defective in infecting cells under standard conditions, but can infect cells if centrifuged onto the host cells. The plasmid-deficient strains were able to infect mice with little or no pathological symptoms, and reduced the pathology in mice later challenged with the parental wild-type disease-causing Chlamydia strain. Thus, plasmid-deficient Chlamydia are effective vaccine strains. The invention provides a process for isolating a plasmid-deficient strain of Chlamydia sp., a process for developing a plasmid-deficient strain of Chlamydia sp. for use as a vaccine, a process for developing a highly infective plasmid-deficient strain of Chlamydia sp., isolated Chlamydia sp. strains, a method of expressing a recombinant nucleic acid in Chlamydia sp., and a method of immunizing a mammal against a Chlamydia infection.
Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
Risk Summary   
There are no data on the presence of repaglinide in human milk, the effects on the breastfeeding infant, or the effects on milk production. The drug is present in animal milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk (see Data). Because of the potential for hypoglycemia in breastfed infants, repaglinide tablets is not recommended for use when breastfeeding.  
Data   
In rat reproduction studies, measurable levels of repaglinide were detected in the breast milk of the dams and lowered blood glucose levels were observed in the pups. Cross fostering studies indicated that skeletal changes [see Use in Specific Populations (8.1)] could be induced in control pups nursed by treated dams, although this occurred to a lesser degree than those pups treated in utero.
A mental health response system and method is provided. The system and method provide guidance and support to first responders, mental health medical care providers, and others that are tasked to respond to incidents involving potential mental health crisis. The system and method inputs information regarding the incident and the patient involved in the incident and determines an incident response recommendation. The system and method provides the formulated incident response recommendation to the first responders via a mobile application. The system and method uses machine learning to determine the incident recommendation as well as follow-up medical treatment for the patient. The system and method administers the particular formulated healthcare treatment to the respective patient.
OBJECTIVE: To conduct a systematic review of studies on various posterior pedicle screw fixation (PSF) methods used for treating neurologically intact thoracolumbar burst fractures and to identify the most effective and safe approaches.
METHODS: We conducted a systematic review adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, with the study registered in PROSPERO (CRD42024531093). The inclusion criteria were: (1) publication dates from January 1, 2004, to December 31, 2023; (2) availability of full-text articles in English; (3) thoracolumbar burst fractures without neurological deficits; (4) patients aged over 18; (5) reports on treatment outcomes or complications; (6) a mean follow-up period of at least 12 months.
RESULTS: A total of 69 articles covering 116 patient groups were included. Our analysis highlighted the advantages of short-segment fixation without fusion over monosegmental, short-segment and long-segment fusion in terms of shorter operation times and reduced intraoperative blood loss (p = 0.001 and p < 0.001, respectively). Extensive fusion was associated with a significantly higher frequency of deep surgical site infections compared to other PSF methods (p = 0.043). Percutaneous pedicle screw fixation, applied to patients with lower body compression rates and kyphotic deformities, led to less potential for correction (p = 0.004), yet significantly decreased blood loss (p = 0.011), operation duration (p < 0.0001), and hospitalization duration (p < 0.0001). No significant benefits were observed with the use of additional intermediate screws in short-segment PSF.
CONCLUSIONS: Short-segment pedicle screw fixation could be the optimal surgical treatment method for neurologically intact thoracolumbar burst fractures. The use of posterior lateral fusion in this context may increase the deep surgical site infection rate without reducing the frequency of implant-related complications or improving long-term treatment outcomes. The percutaneous approach remains the preferred technique; however, its limited reduction capabilities should be carefully considered during surgical planning for patients with severe kyphotic deformities. The application of intermediate screws in such patients has not demonstrated significant advantages. Removing the fixation system has not led to a significant decrease in implant-related complications or improvement in quality of life. The data obtained from the systematic review may assist surgeons in selecting the most appropriate surgical treatment method for patients with neurologically intact thoracolumbar burst fractures, thereby avoiding ineffective procedures and improving both short-term and long-term outcomes.
FIELD: medicine. SUBSTANCE: invention relates to preparing biomaterials, namely, to implants used for filling defects in bone. Phosphate cement comprises a dry mixture and collagen-containing bioapatite. Dry mixture contains dicalcium phosphate, tetracalcium phosphate, sodium hydrocarbonate, magnesium carbonate and potassium fluoride and components are taken in the definite quantitative ratio. Cement comprises, wt.-%: dry mixture, 67.8-70.2; composition collagen-containing bioapatite, 29.8-32.0. Cement provides technical parameters of implant corresponding by the composite to inorganic component of osseous tissue. EFFECT: valuable properties of cement. 2 tbl, 5 ex
Chorea is a hyperkinetic movement disorder associated with various underlyingconditions, including autoimmune diseases such as antiphospholipid syndrome (APS). APS can manifest with a wide range of neurological symptoms, including chorea. We present a case of a 77-year-old man with subacute generalized chorea secondary to primary APS. Notably, the patient exhibited a left patellar crossed-reflex, a phenomenon rarely documented in chorea cases, the pathophysiology of which has not yet been elucidated. In summary, this case challenges the traditional demographics of antiphospholipid syndrome (APS) by suggesting a potential link between APS and late-age patients. It emphasizes the importance of considering APS in late-onset chorea cases.
Patients randomized to the experimental arm will receive dexmedetomidine. At initiation, a bolus will NOT be administered. In keeping with Health Canada. Guidelines, the infusion will start at a mid-range dose of 0.6mcg/kg/h with titration either up or down by 0.1mcg/kg/h every 20-30 minutes to a maximum rate of 1.2mcg/kg/h to maintain light sedation (Richmond Agitation-Sedation Scale \[RASS\] = -2 to +1 or Riker Sedation-Agitation Scale \[SAS\] 3-4).
The aim of this study was to describe the goals, activities, and methods of EUMOVE project in developing a set of resources targeting both primary and secondary schools that allow the entire educational community to promote healthy lifestyles (HL). The EUMOVE project is an Erasmus+ program based in the Creating Active Schools (CAS) framework. The project lasted 3 years and was developed by 14 academic and non-governmental institutions from Spain, Portugal, France, Italy, and the UK. EUMOVE was divided into three phases. In the first phase, several work packages were carried out aimed to ensure the coordination/management of the project activities. In the second phase, seven educational resources strengthened by rigorous scientific research were developed to promote HL from schools. During the last phase, all the resources were disseminated through scientific seminars, workshops with families and teachers, and the online promotion by the non-governmental institutions of each country. The EUMOVE project developed and promoted a smartphone APP, video/activity repository of physically active lessons, active break virtual platform, learning units, and parent/teachers/school-leaders' guidelines to promote physical activity, active commuting, active school playgrounds, healthy diet, and sleep habits. To our knowledge, EUMOVE is the first European project to provide a set of practical tools based on scientific evidence to help schools or future school-wide interventions implement a paradigm shift based on the CAS framework for the promotion of HL. Future research will need to investigate the implementation, effectiveness, and scalability of this proposal.
PURPOSE: The success of metabolic and bariatric surgery (MBS) is impacted by significant pre-surgical attrition rates and poor postoperative follow-up. This study focused on geographic variations in attrition rates and surgical outcomes for MBS practice for which the patient population is drawn from nine Chicago neighborhoods, to examine whether suboptimal weight loss or reduced adherence to the program varied across neighborhoods.
METHODS: Patients who presented for their initial MBS consultation at the University of Illinois (UI) Health's program between January 2019 and December 2020 were identified from electronic medical records. Demographic and medical information was extracted, along with postoperative weight at 3, 6, and 12 months after surgery. The Chicago area was divided into nine geographic regions. The outcomes of interest were preoperative attrition rate, postoperative compliance to follow-up appointments, and postoperative weight loss for each group and by residential neighborhood.
RESULTS: A total of 1202 patients were included in this analysis, of whom 423 (35%) underwent surgery and 780 did not, representing a pre-surgical attrition rate of 64.9%. Age, sex, and race/ethnic distribution varied markedly across geographic regions. Postoperative weight loss varied significantly in neighborhoods with higher proportions of residents from racial/ethnic minority backgrounds. Preoperative attrition and postoperative compliance did not differ across geographic regions.
CONCLUSION: Patients' residential neighborhoods may influence weight loss after MBS. Preoperative and postoperative compliance did not vary by residential neighborhood.